121345-64-0

Basic information

• Product Name: N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine
• Synonyms: benzeneethanamine, 3,4-dimethoxy-N-methyl-N-[3-[4-[[1-methyl-2-(1-methylethyl)-1H-indol-3-yl]sulfonyl]phenoxy]propyl]-
• CAS NO: 121345-64-0
• Molecular Formula: C₃₂H₄₀N₂O₅S
• Molecular Weight: 564.7354
• Mol File: 121345-64-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 724.1°C at 760 mmHg
• Flash Point: 391.7°C
• Density: 1.15g/cm³
• Vapor Pressure: 8.05E-21mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine(121345-64-0)
• EPA Substance Registry System: N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[1-methyl-2-(propan-2-yl)-1H-indol-3-yl]sulfonyl}phenoxy)propan-1-amine(121345-64-0)

Safety Data

• Hazardous Substances Data: 121345-64-0(Hazardous Substances Data)

Upstream product

• 121347-04-4 1-methyl-2-isopropyl-3-<(4-methoxyphenyl)sulfonyl>indole 
• 121346-99-4 2-isopropyl-3-(4-methoxy-benzenesulphonyl)-indole 
• 36770-74-8 N-(3-chloropropyl)-3,4-dimethoxy-N-methylphenethylamine 
• 121347-06-6 1-Methyl-2-isopropyl-3-(4-hydroxy-benzenesulphonyl)indole 

Relevant articles and documents

Novel heterocyclic analogues of the new potent class of calcium entry blockers: 1-[[4-(aminoalkoxy)phenyl]sulfonyl]indolizines

Several heterocyclic analogues of the potent 1-[[4- (aminoalkoxy)phenyl]sulfonyl]indolizines were synthesized and evaluated for their antagonistic calcium activities in comparison with the 1- sulfonylindolizine SR 33557 and the usual calcium antagonist re

Alkyl- or aryl-aminoalkoxy-benzene-sulfonyl indoles

The present invention relates to aminoalkoxyphenyl derivatives of formula: STR1 and its N-oxide and pharmaceutically acceptable salts, in which: B represents a--S--, --SO-- or --SO2 -- group, R1 and R2, which are identical or different, each denote hydrogen, a methyl or ethyl radial or a halogen atom, A denotes a straight-or branched-alkylene radical having from 2 to 5 carbon atoms or a 2-hydroxypropylene radial in which the hydroxy is optionally substituted by a lower alkyl radical, R3 denotes an alkkyl radical or a radical of formula: in which Alk denotes a single bond or a linear- or branched-alkylene radical having from 1 to 5 carbon atoms and Ar denotes a pyridyl, phenyl, 2,3-methylenedioxyphenyl or 3,4-methylenedioxyphenyl radical or a phenyl group substituted with one or more substituents, which may be identical or different, selected from halogen atoms, lower alkyl group or lower alkoxy groups, R11 denotes hydrogen or a lower alkyl, phenyl, diphenylmethyl, benzyl or halogenobenzyl radical, R4 denotes hydrogen or an alkyl radical, or R3 and R4 when taken together denote an alkylene or alkenylene radical having from 3 to 6 carbon atoms and optionally substituted with a phenyl radical or optionally interrupted by STR2 R represent hydrogen, an alkyl radical, a cycloalkyl radical, a benzyl radical or a phenyl radical optionally substituted with one or more substituents, which may be identical or different, selected from halogen atoms and from lower alkyl, lower alkoxy or nitro groups, are described. The compounds of the invention possess exceptional pharmacological properties, especially calcium transport inhibitory properties, as well as bradycardic, hypotensive and antiadrenergic properties.